Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Placebo-Controlled Pilot Study
Naghibi M, Pont-Beltran A, Lamelas A, Llobregat L, Martinez-Blanch JF
Published in Nutrients
Methodology
Randomised, double-blind, placebo-controlled pilot trial in 60 healthy adults with mild-to-moderate digestive symptoms taking heat-treated B. longum CECT 7347 or placebo for 8 weeks with follow-up at week 10.
Key Findings
Minimal change in gastrointestinal symptom scores, but significant decreases in total and non-HDL cholesterol, increases in butyrate-producing Faecalibacterium and Anaerobutyricum, and stable faecal calprotectin versus a rise in placebo.
Conclusions
Heat-treated B. longum CECT 7347 may support gut health markers and lower serum cholesterol, though symptom benefit was minimal.
Limitations
Pilot study with 60 participants; symptom endpoints largely unchanged; exploratory biomarker analyses.
Supplements Studied
While minimal changes were observed in gastrointestinal (GI) symptoms, the HT-ES1 group showed a significant decrease in total and non-HDL cholesterol compared to the placebo.
Outcomes Measured
Faecal calprotectin significantly increased over time in the placebo group but remained stable in the HT-ES1 group.
The intervention group also exhibited a significant increase in the abundance of the genera Faecalibacterium and Anaerobutyricum, both of which were positively correlated with butyrate concentrations.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Industry (probiotic manufacturer) funded
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.